scholarly journals Correlation between Plasma Osteopontin and Alkaline Phosphatase in Type 2 Diabetes Mellitus Patients

2020 ◽  
Vol 26 (2) ◽  
Author(s):  
Josua TH Sinambela ◽  
M.I Diah Pramudianti ◽  
Dian Ariningrum
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Alkaline Phosphatase ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Postprandial Blood Glucose ◽  
P Value ◽  
Healthy Controls ◽  
Type 2 Dm

Diabetes Mellitus (DM) is a chronic disease caused by pancreas the inability to produce insulin or ineffectively insulin use.Fracture risk in type 2 DM patients increases even though the bone density is normal. This study aimed to examine thecorrelation of osteopontin (OPN) and alkaline phosphatase (ALP) in type 2 DM patients. An observational analytical studywas conducted in 73 type 2 DM patients in Dr. Moewardi Hospital, Surakarta from October to November 2018. The subjectswere examined for blood pressure, fasting blood glucose, two hours postprandial blood glucose, HbA1c, OPN, and ALPlevels. P-value <0.05 was statistically significant with a 95% confidence interval. Poorly controlled type 2 DM had higher OPNlevels than well-controlled (20.5±2.8 vs. 14.8±3.1 ng/mL, p <0.001). The ALP concentration was also higher in poorlycontrolled type 2 DM patients (79.9±31.7 vs. 61.1±25 U/L, p=0.003). The levels of OPN and ALP were significantly correlatedin type 2 diabetes (r=0.273; p=0.020) and in well-controlled patients (r=0.353; p=0.047) but no correlation was found inpoorly controlled type 2 DM patients (r= -0.073; p= 0.652). In this study, a significant correlation was found between OPNand ALP in patients with type 2 DM and well-controlled. Further study involving healthy controls and bone ALPmeasurement is needed.

scholarly journals Efficacy and safety of bromocriptine quick release as an add on therapy with metformin and glipizide in type 2 diabetes mellitus patients: an open label randomized controlled study

2019 ◽  
Vol 8 (4) ◽  
pp. 669
Author(s):  
Nithyapriya M. ◽  
S. Purushotaman
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Postprandial Blood Glucose ◽  
Control Group ◽  
Study Group ◽  
Quick Release ◽  
Type 2 Dm

Background: Type 2 Diabetes Mellitus (DM) is a metabolic disorder, treated by insulin and oral hypoglycaemic agents (OHA). Despite treatment, to protect diabetic population from its complications is difficult. So, there is a need for an OHA with different mechanism of action and minimal side effects. Bromocriptine Mesylate QR (Quick release) formulation was approved by FDA for treatment of type 2 DM. Hence, this study was planned to highlight the usefulness of Bromocriptine QR in type 2 diabetes mellitus.Methods: Total 140 patients with type 2 DM were randomized into two groups. The control group was treated with Metformin 500 mg BD (twice daily) and Glipizide 5 mg BD for a period of 3 months. The study group received Bromocriptine quick release 1.6 mg once daily, metformin 500 mg BD and Glipizide 5 mg BD for a period of 3 months. In both control and study groups, fasting blood glucose, postprandial blood glucose was monitored at 0, 1st, 2nd and 3rd month. HbA1C was done at baseline and at the end of 3 months.Results: There was statistically significant decrease in fasting blood glucose, postprandial blood glucose and HbA1C when compared to baseline in both control group (p <0.05) and study group (p <0.05) at the end of 3 months. But the decrease in FBS, PPBS, HbA1C was higher in the study group (p=0.0001) than the control group (p=0.001).Conclusions: In type 2 DM patients, Bromocriptine QR, combined with metformin and Glipizide reduced fasting and postprandial blood glucose and HbA1C significantly compared to metformin and glipizide alone.

scholarly journals The Effects of Tai Chi on Type 2 Diabetes Mellitus: A Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Mengyao Chao ◽  
Chunyan Wang ◽  
Xiaosheng Dong ◽  
Meng Ding
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Tai Chi ◽  
Meta Analysis ◽  
Postprandial Blood Glucose ◽  
Type 2 Dm ◽  
Significant Difference

Objective. To investigate the effects of Tai chi in type 2 diabetes mellitus (type-2 DM) patients using systematic review and meta-analysis. Methods. Seven electronic resource databases were searched, and randomized controlled trials on the role of Tai chi in type-2 DM patients were retrieved. The meta-analysis was performed with RevMan 5.3, and research quality evaluation was conducted with the modified Jadad scale. Results. Fourteen studies, with 798 individuals related to the intervention of Tai chi on diabetes, were included. The results showed that, compared with nonexercise, Tai chi had the effect of lowering fasting blood glucose [MD = −1.39, 95% CI (−1.95, −0.84), P<0.0001] and the subgroup effect size decreased with the increase of total exercise amount, there is no significant difference between Tai chi and other aerobic exercises [MD = −0.50, 95% CI (−1.02, 0.02), P=0.06]; compared with nonexercise, Tai chi could reduce HbA1c [MD = −0.21, 95% CI (−0.61, 0.19), P=0.31], and the group effect size decreased with the increase of total exercise amount. The reducing HbA1c effect of Tai chi was better than that of other aerobic exercises, but the difference was at the margin of statistical significance [MD = −0.19, 95% CI (−0.37, 0.00), P=0.05]; compared with nonexercise, Tai chi had the effect of reducing 2 h postprandial blood glucose [MD = −2.07, 95% CI (−2.89, −1.26), P=0.0002], there is no significant difference between Tai chi and other aerobic exercises in reducing 2 h postprandial blood glucose [MD = −0.44, 95% CI (−1.42, 0.54), P=0.38]. Conclusion. Tai chi can effectively affect the management of blood glucose and HbA1c in type-2 DM patients. Long-term adherence to Tai chi has a better role in reducing blood glucose and HbA1c levels in type 2 DM patients.

scholarly journals Hubungan Antara Tingkat Stres Dan Kadar Glukosa Darah Puasa Penderita Diabetes Melitus Tipe 2 Di Kecamatan Maos

2019 ◽  
Vol 8 (1) ◽  
Author(s):  
Esti Oktaviani Purwasih
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Stress Level ◽  
Fasting Blood Glucose ◽  
P Value ◽  
Cross Sectional ◽  
Diabetes Melitus

ABSTRAKDiabetes melitus (DM) tipe 2 yaitu penyakit gangguan metabolik ditandai kenaikan gula darah karena penurunan sekresi insulin oleh sel beta pankreas dan atau ganguan resistensi insulin.Penelitian ini bertujuan untuk mengidentifikasi hubungan antara kadar glukosa darah puasa dengan tingkat stres pada penderita diabetes melitus (DM) tipe 2. Jenis penelitian adalah deskriptif korelasi dengan pendekatan cross sectional. Variabel independen dalam penelitian ini yaitu tingkat stres. Sedangkan variabel dependen dalam penelitian ini yaitu kadar glukosa darah puasa. Penelitian dilakukan di Puskesmas Maos dan Klinik Graha Amanah Maos bulan Maret 2017. Sampel diambil dengan total sampling, berjumlah  60 responden yang menderita DM tipe 2 minimal 1 tahun, memiliki kadar GDP 130 mg/dl, dan tidak memiliki penyakit komplikasi seperti gagal ginjal kronis, dan kanker.Hasil analisis data menggunakan spearman rho didapatkan tidak terdapat hubungan antara kadar glukosa darah puasa dan tingkat stres (p value = 0,137). Kata Kunci: Diabetes Mellitus Tipe 2, Glukosa Darah Puasa, Tingkat Stres. ABSTRACTType 2 diabetes mellitus (DM ) is a metabolic disease that characterized by an increasing of  blood  glucose because of decreasing insulin secretion by pancreatic beta cells and or insulin resistance disorders.This research aimed to identify the relationship between fasting blood glucose (FBG) level and stress level in patients with  type 2 diabetes mellitus (DM). The research design was descriptive correlation with cross sectional approach. The independent variable in this study was stress level. The dependent variable in this study was fasting blood glucose level. The study was at Maos Community Health Center and Graha Amanah Clinic in March 2017.The sample was total sampling. These were 60 respondents who diagnosed  type 2 diabetes mellitus at least 1 year, had FBG level 130 mg / dl, and did not have complications such as chronic kidney failure , and cancer.The results of data analysis by using spearman rho found that there was no correlation between fasting blood glucose level and stress level (p value = 0.137). Keywords: Type 2 Diabetes Mellitus, Fasting Blood Glucose, Stress Level.

Comparison of Metformin-Sulfonylurea and Metformin-Acarbose Combination Therapies on Glycemic Outcomes: A Retrospective Cohort Study

2021 ◽  
Vol 18 ◽  
Author(s):  
Wafa ◽  
Renni Septini ◽  
Rani Sauriasari
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cohort Study ◽  
Blood Glucose ◽  
Retrospective Cohort ◽  
Fasting Blood Glucose ◽  
Postprandial Blood Glucose ◽  
Combination Therapies

Objective: Pharmacological therapy for type 2 diabetes mellitus features various combinations of treatments, with different therapies providing different levels of effectiveness. In clinical settings, choices are driven by cost, effectiveness, and safety considerations, and these choices are still under question in Indonesia. This study aimed to compare the effectiveness of metformin-sulfonylurea and metformin-acarbose combination therapies on glycemic parameters in patients with type 2 diabetes mellitus. Methods: This study was carried out at Gatot Soebroto Army Hospital in Jakarta and utilized a retrospective cohort study design. Participants had consumed the same drug without switching for six months and were divided into a metformin-sulfonylurea group (n = 100) and a metformin-acarbose group (n = 100). The effectiveness of treatment was evaluated by considering hemoglobin A1c (HbA1c), two hours postprandial glucose, and fasting blood glucose. Results: After six months’ consumption, there were no statistical differences between results for the metformin-sulfonylurea and metformin-acarbose groups in terms of change of HbA1c (p = 0.062), controlled two hours postprandial blood glucose (p = 0.649), and controlled fasting blood glucose (p = 0.282). Regular exercise was the most significant factor for constant/decreased HbA1c, whereas being male and following a diet were the most significant factors for controlled two hours postprandial blood glucose and fasting blood glucose, respectively. Conclusion: Based on the analysis performed, there was no significant difference in the effectiveness of six months’ consumption of metformin-sulfonylurea and metformin-acarbose on HbA1c, two hours postprandial blood glucose, and fasting blood glucose.

scholarly journals The Effects of Qigong on Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Ding Meng ◽  
Wang Chunyan ◽  
Dong Xiaosheng ◽  
Yi Xiangren
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Meta Analysis ◽  
Postprandial Blood Glucose ◽  
Positive Effects ◽  
Type 2 Dm

Objective. The purpose of this study was to investigate the effects of Qigong on type 2 diabetes mellitus (DM) using the systematic review and meta-analysis. Methods. All prospective, randomized, controlled clinical trials published in English or Chinese and involving the use of Qigong by patients with DM were searched in 7 electronic databases from their respective inception to June 2016. The meta-analysis was conducted using the Revman 5.2. The quality of the included trials was assessed using the Jadad rating scale. Two researchers independently completed the inclusion, data extraction, and quality assessment. Results. Twenty-one trials with 1326 patients met the inclusion criteria and were reviewed. The meta-analysis demonstrated that, compared with no exercise, the Qigong had significant effects on fasting blood glucose (MD = −0.99, 95% CI (−1.23, 0.75), P<0.0001), HbA1c (MD = −0.84, 95% CI (−1.02, −0.65), P<0.0001), and postprandial blood glucose (MD = −1.55, 95% CI (−2.19, −0.91), P<0.00001). Conclusion. The Qigong training can improve the blood glucose status of the type 2 DM patients and has positive effects on the management of type 2 DM. However, future research with better quality still needs to be conducted to address the effects of Qigong on type 2 DM.

scholarly journals NCEP-ATP III and IDF criteria for metabolic syndrome predict type 2 diabetes mellitus

2016 ◽  
Vol 35 (1) ◽  
pp. 46 ◽  
Author(s):  
Eva Sulistiowati ◽  
Marice Sihombing
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
Cohort Study ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Screening Programs ◽  
Type 2 Dm

<p><strong>Background</strong><strong></strong></p><p>Subjects with metabolic syndrome (MetS) have a greater risk for acquiring type 2 diabetes mellitus (type 2 DM). The MetS criteria usually used are those of the National Cholesterol Education Program Expert Panel (NCEP) and Adult Treatment Panel III (ATP III) and of the International Diabetes Federation (IDF). This study aimed to evaluate the modified NCEP-ATP III and IDF criteria as predictor of type 2 DM among subjects with MetS.</p><p> </p><p><strong>Methods</strong></p><p>A cohort study was conducted among 4240 subjects with MetS. MetS was determined according to the modified NCEP-ATP III and IDF criteria. The study followed up 3324 non-diabetic subjects of the cohort study of non-communicable disease (NCD) risk factors (NCD study) during a 2-year period. Type 2 DM was determined from the diagnosis by health personnel or from fasting blood glucose of ≥126 mg/dL or blood glucose of ≥200 mg/dL, 2 hours after 75g glucose loading.</p><p> </p><p><strong>Results</strong></p><p>The MetS prevalence based on modified NCEP ATP III and IDF criteria in non-DM subjects was 17.1% and 15.6%, respectively. The risk for DM in subjects with MetS using modified NCEP ATP III and IDF criteria was 4.7 (CI 95%: 3.4-6.5) and 4.1 (CI 95%: 3.0-5.7), respectively.</p><p> </p><p><strong>Conclusions</strong></p><p>Both MetS criteria can be used as predictors of the occurrence of DM type 2, but the modified NCEP-ATP III is more properly applied than the IDF criteria in subjects with MetS. Screening programs and routine monitoring of MetS components are required for early detection of type 2 DM.</p>

scholarly journals TYPE 2 DIABETES MELLITUS;

2019 ◽  
Vol 26 (04) ◽  
Author(s):  
Doctor Dilshad Muhammad ◽  
Masood Javed ◽  
Muzzammal Iftikhar
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
P Value ◽  
Group A ◽  
Group B ◽  
New Onset

Background: Diabetic complications are related to impaired glycemic control. The UK Prospective Diabetes Study (UKPDS) showed that metformin therapy in overweight and obese patients with type 2 diabetes mellitus (T2DM) could reduce HbA1c and complications. So, metformin has been suggested to be the drug of choice after life style modifications in patients with T2DM. Repaglinide, short-acting insulin secretagogues, has excellent anti-hyperglycemic effect and a lower risk of hypoglycemia. However, whether repaglinide can be used as an initial therapy in patients with newly diagnosed T2DM is still unconfirmed. Objectives: The objective of this study was: To compare efficacy of Repaglinide and Metformin in the Treatment of New Onset Type 2 Diabetes Mellitus. Study Design: Randomized Controlled Trial. Setting: District headquarter Hospital, Faisalabad. Period: 6 Months (Jan 2018 to June 2018). Methodology: Patients were randomly divided into two groups (A & B) by using computer generated random number table. Group A was given repaglinide 0.75-1.5 mg/day while group B received metformin 750-1500mg/day. The doses of metformin and repaglinide were adjusted according to blood glucose level. For HbA1C and FBS, blood samples were sent to pathology laboratory at the start of study and after 3 months. Follow up was ensured by reaching the patients through telephonic contact. Data was collected through self-conducted interviews using a standardized Performa. Results: In our study, mean+sd was calculated as 44.54+5.92 years in Group-A and 45.31+6.13 years in Group-B, 42.86%(n=15) in Group-A and 40%(n=14) in Group-B were male whereas 57.14%(n=20) in Group-A and 60%(n=21) in Group-B were females. Baseline mean HbA1c levels of the patients were calculated as 7.51+0.50 mmol/L in Group-A and 7.54+0.52 mmol/L in Group B, p value was 0.81. After treatment, these findings were reduced to 5.57+0.65 in Group-A and 6.4+0.49 in Group-B, p value was 0.0001, At baseline mean fasting blood glucose levels of the patients were calculated as 7.43+0.56 mmol/L in Group-A and 7.46+0.50 mmol/L in Group B, p value was 0.82. After treatment, these findings were reduced to 5.83+0.71 in Group-A and 6.29+0.67 in Group-B, p value was 0.007. Conclusion: We concluded that on comparison of Metformin and Repaglinide monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in terms of mean fasting blood glucose and mean HbA1c, both drugs reduced HbA1c and fasting blood sugar but Repaglinide was found significantly better for reduction of HbA1c and fasting blood sugar when compared to Metformin.

Sign in / Sign up

Export Citation Format

Share Document